Genetics of Long QT and Short QT Syndromes


Long QT syndrome (LQTS) is the best described inheritable arrhythmogenic disorder. It is characterised by a increased duration of cardiac action potential secondary either to mutations that produce a loss‐of‐function of potassium channels responsible for cardiac repolarisation or to gain‐of‐function alterations of sodium channels responsible for cardiac depolarisation. Seventeen genes have been associated with LQTS. The first three genotypes discovered (LQT1–LQT3) account for 95% of genotype‐positive cases. Genetic analysis allows to identify the pathogenic genetic defect in 80% of patients and plays a crucial role in the diagnosis, risk stratification and treatment.

Conversely, short QT syndrome (SQTS) is the latest described inheritable arrhythmogenic disease, and its genetic basis has been poorly clarified. It is characterised by an abnormal shortening of the cardiac repolarisation, which may result either from gain‐of‐function mutations of potassium channels responsible for cardiac repolarisation or from a diminished function of voltage‐dependent‐L‐type calcium channels responsible for cardiac depolarisation. The five genetic forms of the disease identified account for only 20% of SQTS patients. Therefore, genetic analysis portends a limited contribution to the diagnosis and management of SQTS patients.

Key Concepts

  • Long QT syndrome (LQTS) is the best described monogenic inherited arrhythmogenic disorder, with 17 disease‐related genes described to date. The first three genotypes discovered represent about 75% of all LQTS cases.
  • The common pathophysiological substrate of LQTS variants is represented by a prolongation of cardiac repolarisation that can be secondary either to loss‐of‐function defects of potassium channels responsible for cardiac repolarisation or to gain‐of‐function alterations of sodium channels responsible for cardiac depolarisation.
  • Genetic analysis allows to identify the pathogenic defect in 80% of LQTS patients and therefore plays a crucial role in the diagnosis, risk stratification and therapeutic approach of LQTS patients.
  • Short QT syndrome (SQTS) is the latest described inherited arrhythmogenic disorder, and its genetic basis has been scarcely understood. To date, five genetic forms of the disease have been identified.
  • Genetic analysis allows to identify the pathogenic defect in only 20% of SQTS affected individuals.
  • The pathophysiological substrate of SQTS resides in an abnormal shortening of cardiac repolarisation, which can be secondary to gain‐of‐function mutations harboured in potassium channels or to loss‐of‐function defects of voltage‐dependent L‐type calcium channels.
  • Due to the lack of genotype–phenotype correlation information to this date and due to the low yield of genetic testing, in SQTS genetic analysis does not help in risk stratification and clinical management of affected individuals.

Keywords: channelopathies; long QT syndrome; short QT syndrome; sudden cardiac death; Torsades de Pointes; genetics; mexiletine

Figure 1. Examples of electrocardiograms of patients with Long QT Syndrome and Short QT Syndrome. (a) The electrocardiogram of a patient with Long QT Syndrome type 3 (LQT3). Note the typical sinus bradycardia and the broad‐based T wave with late onset. RR: 1500 ms; QT: 720 ms; QTc: 588 ms. (b) ECG example of an asymptomatic Short QT type Syndrome type 3 (SQT3) patient. RR: 850 ms; QT: 310 ms; QTc: 336 ms.
Figure 2. Basal ECG of a 20‐year‐old patient with Andersen–Tawil syndrome. The trace shows the typical prominent U waves (see the asterisk) and frequent ventricular ectopic beats.


Abbott GW, Sesti F, Splawski I, et al. (1999) MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97 (2): 175–187.

Ackerman MJ, Priori SG, Willems S, et al. (2011) HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Europace 13 (8): 1077–1109.

Altmann HM, Tester DJ, Will ML, et al. (2015) Homozygous/compound heterozygous triadin mutations associated with autosomal‐recessive long‐QT syndrome and pediatric sudden cardiac arrest: elucidation of the triadin knockout syndrome. Circulation 131 (23): 2051–2060.

Antzelevitch C, Pollevick GD, Cordeiro JM, et al. (2007) Loss‐of‐function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST‐segment elevation, short QT intervals, and sudden cardiac death. Circulation 115 (4): 442–449.

Barsheshet A, Goldenberg I, O‐ Uchi J, et al. (2012) Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life‐threatening events: implications for mutation‐specific response to beta‐blocker therapy in type 1 long‐QT syndrome. Circulation 125 (16): 1988–1996.

Bellocq C, van Ginneken AC, Bezzina CR, et al. (2004) Mutation in the KCNQ1 gene leading to the short QT‐interval syndrome. Circulation 109 (20): 2394–2397.

Boczek NJ, Gomez‐Hurtado N, Ye D, et al. (2016) Spectrum and prevalence of CALM1‐, CALM2‐, and CALM3‐encoded calmodulin variants in long QT syndrome and functional characterization of a novel long QT syndrome‐associated calmodulin missense variant, E141G. Circulation. Cardiovascular Genetics 9 (2): 136–146.

Brugada R, Hong K, Dumaine R, et al. (2004) Sudden death associated with short‐QT syndrome linked to mutations in HERG. Circulation 109 (1): 30–35.

Chen L, Marquardt ML, Tester DJ, et al. (2007) Mutation of an A‐kinase‐anchoring protein causes long‐QT syndrome. Proceedings of the National Academy of Sciences 104 (52): 20990–5.

Crotti L, Johnson CN, Graf E, et al. (2013) Calmodulin mutations associated with recurrent cardiac arrest in infants. Circulation 127 (9): 1009–1117.

Curran ME, Splawski I, Timothy KW, et al. (1995) A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80 (5): 795–803.

Harrell DT, Ashihara T, Ishikawa T, et al. (2015) Genotype‐dependent differences in age of manifestation and arrhythmia complications in short QT syndrome. International Journal of Cardiology 190: 393–402.

Makita N, Yagihara N, Crotti L, et al. (2014) Novel calmodulin (CALM2) mutations associated with congenital arrhythmia susceptibility. Circulation. Cardiovascular Genetics 7: 466–474.

Mazzanti A, Kanthan A, Monteforte N, et al. (2014) Novel insight into the natural history of short QT syndrome. Journal of the American College of Cardiology 63 (13): 1300–1308.

Mazzanti A, Maragna R, Faragli A, et al. (2016) Gene‐specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. Journal of the American College of Cardiology 67 (9): 1053–1058.

Medeiros‐Domingo A, Kaku T, Tester DJ, et al. (2007) SCN4B‐encoded sodium channel beta4 subunit in congenital long‐QT syndrome. Circulation 116 (2): 134–142.

Moss AJ, Zareba W, Kaufman ES, et al. (2002) Increased risk of arrhythmic events in long‐QT syndrome with mutations in the pore region of the human ether‐a‐go‐go‐related gene potassium channel. Circulation 105 (7): 794–799.

Priori SG, Schwartz PJ, Napolitano C, et al. (2003) Risk stratification in the long‐QT syndrome. New England Journal of Medicine 348 (19): 1866–1874.

Priori SG, Napolitano C, Schwartz PJ, et al. (2004) Association of long QT syndrome loci and cardiac events among patients treated with beta‐blockers. JAMA 292 (11): 1341–1344.

Priori SG, Pandit SV, Rivolta I, et al. (2005) A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circulation Research 96 (7): 800–807.

Priori SG, Wilde AA, Horie M, et al. (2013) HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 10 (12): 1932–1963.

Priori SG, Blomstrom‐Lundqvist C, Mazzanti A, et al. (2015) 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). European Heart Journal 36 (41): 2793–2867.

Roux‐Buisson N, Cacheux M, Fourest‐Lieuvin A, et al. (2012) Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human. Human Molecular Genetics 21 (12): 2759–2767.

Ruan Y, Liu N, Bloise R, et al. (2007) Gating properties of SCN5A mutations and the response to mexiletine in long‐QT syndrome type 3 patients. Circulation 116 (10): 1137–1144.

Schott JJ, Charpentier F, Peltier S, et al. (1995) Mapping of a gene for long QT syndrome to chromosome 4q25‐27. American Journal of Human Genetics 57 (5): 1114–1122.

Schwartz PJ, Priori SG, Spazzolini C, et al. (2001) Genotype‐phenotype correlation in the long‐QT syndrome: gene‐specific triggers for life‐threatening arrhythmias. Circulation 103 (1): 89–95.

Schwartz PJ, Stramba‐Badiale M, Crotti L, et al. (2009) Prevalence of the congenital long‐QT syndrome. Circulation 120 (18): 1761–1767.

Splawski I, Tristani‐Firouzi M, Lehmann MH, et al. (1997) Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nature Genetics 17 (3): 338–340.

Splawski I, Timothy KW, Sharpe LM, et al. (2004) Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119 (1): 19–31.

Templin C, Ghadri JR, Rougier JS, et al. (2011) Identification of a novel loss‐of‐function calcium channel gene mutation in short QT syndrome (SQTS6). European Heart Journal 32 (9): 1077–1088.

Tranebjaerg L, Bathen J, Tyson J and Bitner‐Glindzicz M (1999) Jervell and Lange‐Nielsen syndrome: a Norwegian perspective. American Journal of Medical Genetics 89 (3): 137–146.

Ueda K, Valdivia C, Medeiros‐Domingo A, et al. (2008) Syntrophin mutation associated with long QT syndrome through activation of the nNOS‐SCN5A macromolecular complex. Proceedings of the National Academy of Sciences 105 (27): 9355–9360.

Vatta M, Ackerman MJ, Ye B, et al. (2006) Mutant caveolin‐3 induces persistent late sodium current and is associated with long‐QT syndrome. Circulation 114 (20): 2104–2112.

Wang Q, Shen J, Splawski I, et al. (1995) SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 80 (5): 805–811.

Wang Q, Curran ME, Splawski I, et al. (1996) Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nature Genetics 12 (1): 17–23.

Further Reading

Bohnen MS, Peng G, Robey SH, et al. (2017) Molecular pathophysiology of congenital long QT syndrome. Physiological Reviews 97 (1): 89–134.

Priori SG, Napolitano C, Schwartz PJ, et al. (2000) The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation 102 (9): 945–947.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Maragna, Riccardo, Mazzanti, Andrea, and Priori, Silvia G(Sep 2017) Genetics of Long QT and Short QT Syndromes. In: eLS. John Wiley & Sons Ltd, Chichester. [doi: 10.1002/9780470015902.a0024386]